Researchers plan to monitor the immune responses of COVID-19 patients for one year to see how they correlate with illness severity and lasting effects. This data will help develop personalized treatments for patients.
“The COVID-19 pandemic could be an opportunity for the companies pursuing the development of gene therapies, as few products are in development to fight the viral illness.” Alessio Brunello of GlobalData
To be clear, any adverse event is always one too many. But in the real world, these things happen and often through no intrinsic fault of the therapeutic intervention